Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

Stock factor profile

Balaxi Pharmaceuticals Ltd

BALAXI · Healthcare · Pharmaceuticals & Biotechnology

Balaxi Pharmaceuticals Ltd. engages in the exportation of pharmaceutical, hardware, and FMCG products. The company is headquartered in Hyderabad, Telangana and currently employs 51 full-time employees. The company went IPO on 2015-11-30. The firm is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. The company has a portfolio across multiple therapeutic segments, stock & sell models, and supplying branded and generic medicines. The firm is offerings more than 300 products across multiple therapeutic areas, including Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhoea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its consumer products include Nice 45 G, Guloso 45 G, Snax! 42 G, Doce E Sal 42 G, Yumm 75 G and Boadent.

Last price₹25.80
1 day+3.16%
1 month+7.5%
Model ratingLocked
Data as of04 Sep 2026

Performance

Price history

Equity review factors

Factor profile

Factor scores are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags and screen results for Balaxi Pharmaceuticals Ltd are part of the Wright portfolio review.

Run your free portfolio review

Fundamental snapshot

Fundamentals at a glance

Market cap133
P/E ratio90.0
Factor betaLocked
VolatilityLocked
Model scoreLocked
Screen passLocked

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.